Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.
Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD. Kereiakes DJ, et al. Circ Cardiovasc Interv. 2015 Apr;8(4):e002372. doi: 10.1161/CIRCINTERVENTIONS.114.002372. Circ Cardiovasc Interv. 2015. PMID: 25855680 Free article. Clinical Trial.
A randomized comparison of the effects of gradual prolonged versus standard primary balloon inflation on early and late outcome. Results of a multicenter clinical trial. Perfusion Balloon Catheter Study Group.
Ohman EM, Marquis JF, Ricci DR, Brown RI, Knudtson ML, Kereiakes DJ, Samaha JK, Margolis JR, Niederman AL, Dean LS, et al. Ohman EM, et al. Among authors: kereiakes dj. Circulation. 1994 Mar;89(3):1118-25. doi: 10.1161/01.cir.89.3.1118. Circulation. 1994. PMID: 8124798 Clinical Trial.
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ. Kereiakes DJ, et al. Circulation. 1998 Sep 29;98(13):1268-78. doi: 10.1161/01.cir.98.13.1268. Circulation. 1998. PMID: 9751674 Clinical Trial.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: kereiakes dj. JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853. JAMA. 2003. PMID: 12588269 Clinical Trial.
Vascular brachytherapy boon or bust?
Kereiakes DJ, Willerson JT. Kereiakes DJ, et al. Circulation. 2003 Jul 29;108(4):389-90. doi: 10.1161/01.CIR.0000084892.95826.0A. Circulation. 2003. PMID: 12885732 Review. No abstract available.
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC. Kereiakes DJ, et al. Circulation. 2003 Sep 16;108(11):1310-5. doi: 10.1161/01.CIR.0000087602.91755.19. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939212 Clinical Trial.
579 results